Profitability
Weight: 25%
F
26
- 5yr Avg ROIC 5.3%
- Operating Margin Trend -6.59 pp/yr
LGND
Ligand Pharmaceuticals Incorporated
AlphaQuality composite grade, weighted for platform & compounding fcf businesses.
⚠ 2 of the last 5 fiscal years showed negative net income — AlphaQuality will not grade above F for persistent unprofitability in a platform & compounding fcf business.
Grade overrides the 30.0 pillar composite — hard gates always win.
Capital Efficiency
Weight: 15%
F
21
- 5yr Avg ROE 4.1%
- 5yr Share-Count CAGR 4.6%
Growth Quality
Weight: 25%
B
74
- 5yr Revenue CAGR 10.4%
- Revenue-Growth Years (5) 3/5
Cash Generation
Weight: 20%
B+
76
- 5yr FCF Margin 30.3%
- 5yr FCF/NI Conversion 0.51x
Balance Sheet
Weight: 10%
A+
100
- Net Debt / EBITDA -1.46x
- Interest Coverage (EBIT/Int) 33.71x
- Altman Z-Score 7.87
Stability
Weight: 5%
D-
32
- EPS Volatility (σ/μ) 1.19
- Negative-Revenue Years (5) 2/5
- Piotroski F-Score 5
Guru Flow
Curated superinvestor sentiment — not part of the AlphaQuality grade.3 of 3 gurus held; 2 added; 1 trimmed; 1 full exit.
- Holders
- 3 +1
- Avg Δ position
- +6.9%
- New buys
- 0
- Full exits
- 1
- Dalio sold -100%
- Cooperman increased +27%
- Greenblatt decreased -13%